Wynnefield Locks Up 14.3% Stake Behind Webster Acquisition
LFCR sits 80% above its 52-week low of $3.625 on elevated volume (3.2× avg).
Summary
Wynnefield Capital, Lifecore's largest activist holder at 14.3%, signed a voting agreement backing the Webster Equity Partners acquisition. The filing also confirms Wynnefield's full Series A Preferred redemption demand, payable December 28, 2026.
Key Events · Ownership and Investor Activity · LFCR
-
Wynnefield Signs Voting Agreement
Wynnefield Capital entities, holding 5,512,211 shares (14.3%), agreed to vote all Covered Shares in favor of the Webster Equity Partners merger at $6.28 per share plus CVRs.
-
Transfer Restrictions and Appraisal Waiver
The agreement restricts transfers of Covered Shares until the merger closes and irrevocably waives appraisal rights, locking in Wynnefield's support.
-
Series A Redemption Demand Confirmed
Wynnefield delivered redemption notices for all Series A Preferred Stock on June 30, 2026, with payment due December 28, 2026 — a $52.1 million obligation previously disclosed as exceeding Lifecore's liquidity.
-
Ownership Details
Wynnefield's 14.3% stake includes 644,395 shares issuable upon conversion of Series A Preferred Stock, based on 38,497,455 shares outstanding.
Analysis · LFCR · Life Sciences
Wynnefield Capital, holding 14.3% of Lifecore, signed a voting and support agreement backing the Webster Equity Partners acquisition at $6.28 per share plus CVRs. The agreement locks up 5.5 million shares, waives appraisal rights, and restricts transfers until the merger closes. Wynnefield also delivered redemption notices for all its Series A Preferred Stock on June 30, 2026, with payment due December 28, 2026 — a $52.1 million obligation that exceeds Lifecore's current liquidity and was previously flagged as a going-concern risk. This filing confirms the activist bloc is aligned with the deal, removing a key obstacle to closing.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LFCR was trading at $6.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $249.5M. The 52-week trading range was $3.63 to $8.98. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.